US Stem Cell Inc (USRM)

US Stem Cell, Inc. is a healthcare company focused on the research, development, and commercialization of stem cell and regenerative medicine treatments in the United States and abroad. Its development pipeline includes MyoCell, an autologous muscle stem cell therapy being prepared for Phase II/III clinical trials for heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy that has completed the IND application process for chronic heart damage and blood vessel formation support; and AdipoCell, a clinical protocol and kit being prepared for trials in chronic ischemic cardiomyopathy. In addition to its human therapeutics work, the company provides regenerative medicine solutions for veterinarians and training programs for physicians using bone marrow-derived stem cell protocols. Formerly known as Bioheart, Inc., the company adopted its current name in November 2015. It was incorporated in 1999 and is headquartered in Sunrise, Florida.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.